What is the clinical evidence from this study?

Study design: Case Report. Population: von Willebrand's disease with recurrent gastrointestinal bleeding from angiodysplasia (n=1). Intervention: recombinant activated factor VII (rFVIIa) vs. standard therapy. Primary outcome: Control of bleeding and need for blood transfusions.

What does this research mean for the field?

Recombinant activated factor VII (rFVIIa) can rapidly control recurrent gastrointestinal bleeding from angiodysplasia and eliminate blood transfusion requirements in patients with von Willebrand's disease refractory to standard therapies. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

April 1, 2001Blood Coagulation & Fibrinolysis

Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa

View Full Paper

Ask AI

Bookmark

Key result

Home rFVIIa rapidly controls recurrent GI bleeding and eliminates transfusions in a von Willebrand patient.

Why the study?

Does recombinant activated factor VII (rFVIIa) control recurrent gastrointestinal bleeding in a patient with von Willebrand's disease and angiodysplasia?

Population

1 patient with von Willebrand's disease and recurrent gastrointestinal bleeding from angiodysplasia, with…

Comparison

Home treatment with recombinant activated factor… vs Prior treatments including von Willebrand factor…

Design

Case_report

Authors

KMKarina MeijerVascular Medicine FPFrans PetersUniversity Medical Center Groningen JMJ. van der MeerJan Długosz University

Discussion

Member takes

Overview

May support home rFVIIa for refractory vWD bleeding; hypothesis-generating and requires prospective trials before practice change.

Study Design

Type

Case Report (n=1)

Structured PICO

Does recombinant activated factor VII (rFVIIa) control recurrent gastrointestinal bleeding in a patient with von Willebrand's disease and angiodysplasia?

Population

1 female patient with von Willebrand's disease and recurrent gastrointestinal bleeding from angiodysplasia refractory to standard therapy.

Intervention

Home treatment with recombinant activated factor VII (rFVIIa) at the onset of bleeding, in addition to standard therapy

Comparator

Prior treatments including von Willebrand factor substitution, medical and endoscopic treatment, and bowel resection

Outcome

Control of bleeding and need for blood transfusionshard clinical

Recombinant activated factor VII (rFVIIa) may be an effective therapeutic option for controlling severe recurrent gastrointestinal bleeding from angiodysplasia in patients with von Willebrand's disease.

Cite This Study

Meijer et al. (2001) conducted a case report in von Willebrand's disease with recurrent gastrointestinal bleeding from angiodysplasia (n=1). recombinant activated factor VII (rFVIIa) vs. standard therapy was evaluated on Control of bleeding and need for blood transfusions. Home treatment with recombinant activated factor VII (rFVIIa) rapidly controlled recurrent gastrointestinal bleeding and eliminated the need for blood transfusions in a patient with von Willebrand's disease.

synapsesocial.com/papers/6aa53d10fff38ca398dd4193 https://doi.org/10.1097/00001721-200104000-00008

View Full Paper

Ask AI

Bookmark

April 1, 2001Blood Coagulation & Fibrinolysis

Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa

View Full Paper

Ask AI

Bookmark

Key result

Home rFVIIa rapidly controls recurrent GI bleeding and eliminates transfusions in a von Willebrand patient.

Why the study?

Does recombinant activated factor VII (rFVIIa) control recurrent gastrointestinal bleeding in a patient with von Willebrand's disease and angiodysplasia?

Population

1 patient with von Willebrand's disease and recurrent gastrointestinal bleeding from angiodysplasia, with…

Comparison

Home treatment with recombinant activated factor… vs Prior treatments including von Willebrand factor…

Design

Case_report

Authors

KMKarina MeijerVascular Medicine FPFrans PetersUniversity Medical Center Groningen JMJ. van der MeerJan Długosz University

Discussion

Member takes

Overview

May support home rFVIIa for refractory vWD bleeding; hypothesis-generating and requires prospective trials before practice change.

Study Design

Type

Case Report (n=1)

Structured PICO

Does recombinant activated factor VII (rFVIIa) control recurrent gastrointestinal bleeding in a patient with von Willebrand's disease and angiodysplasia?

Population

1 female patient with von Willebrand's disease and recurrent gastrointestinal bleeding from angiodysplasia refractory to standard therapy.

Intervention

Home treatment with recombinant activated factor VII (rFVIIa) at the onset of bleeding, in addition to standard therapy

Comparator

Prior treatments including von Willebrand factor substitution, medical and endoscopic treatment, and bowel resection

Outcome

Control of bleeding and need for blood transfusionshard clinical

Cite This Study

synapsesocial.com/papers/6aa53d10fff38ca398dd4193 https://doi.org/10.1097/00001721-200104000-00008

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark